Your browser doesn't support javascript.
loading
Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study.
Nishikawa, Yoshitaka; Horimatsu, Takahiro; Oka, Shiro; Yamada, Takeshi; Mitsui, Keigo; Yamamoto, Hironori; Takahashi, Keiichi; Shiomi, Akio; Hotta, Kinichi; Takeuchi, Yoji; Kuwai, Toshio; Ishida, Fumio; Kudo, Shin-Ei; Saito, Shoichi; Ueno, Masashi; Sunami, Eiji; Yamano, Tomoki; Itabashi, Michio; Ohtsuka, Kazuo; Kinugasa, Yusuke; Matsumoto, Takayuki; Sugai, Tamotsu; Uraoka, Toshio; Kurahara, Koichi; Yamaguchi, Shigeki; Kato, Tomohiro; Okajima, Masazumi; Kashida, Hiroshi; Fujita, Fumihiko; Ikematsu, Hiroaki; Ito, Masaaki; Esaki, Motohiro; Kawai, Masaya; Yao, Takashi; Hamada, Madoka; Koda, Keiji; Fukai, Yasumori; Komori, Koji; Saitoh, Yusuke; Kanemitsu, Yukihide; Takamaru, Hiroyuki; Yamada, Kazutaka; Nozawa, Hiroaki; Takayama, Tetsuji; Togashi, Kazutomo; Shinto, Eiji; Torisu, Takehiro; Toyoshima, Akira; Ohmiya, Naoki; Kato, Takeshi.
Afiliación
  • Nishikawa Y; Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
  • Horimatsu T; Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
  • Oka S; Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
  • Yamada T; Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan.
  • Mitsui K; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
  • Yamamoto H; Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan.
  • Takahashi K; Department of Medicine, Division of Gastroenterology, Jichi Medical University, Tochigi, Japan.
  • Shiomi A; Department of Colorectal Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Hotta K; Division of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
  • Takeuchi Y; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
  • Kuwai T; Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Ishida F; Department of Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
  • Kudo SE; Digestive Disease Center, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
  • Saito S; Digestive Disease Center, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
  • Ueno M; Department of Lower Gastrointestinal Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Sunami E; Department of Gastroenterological and Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Yamano T; Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.
  • Itabashi M; Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.
  • Ohtsuka K; Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
  • Kinugasa Y; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Matsumoto T; Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
  • Sugai T; Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
  • Uraoka T; Department of Diagnostic Pathology, Iwate Medical University, Iwate, Japan.
  • Kurahara K; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Yamaguchi S; Division of Gastroenterology, Matsuyama Red Cross Hospital, Ehime, Japan.
  • Kato T; Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
  • Okajima M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Kashida H; Department of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Fujita F; Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
  • Ikematsu H; Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan.
  • Ito M; Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.
  • Esaki M; Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.
  • Kawai M; Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
  • Yao T; Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Hamada M; Department of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Koda K; Department of Gastrointestinal Surgery, Kansai Medical University Hospital, Osaka, Japan.
  • Fukai Y; Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
  • Komori K; Department of Gastroenterology, Maebashi Red Cross Hospital, Gunma, Japan.
  • Saitoh Y; Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
  • Kanemitsu Y; Department of Gastroenterology, Asahikawa City Hospital, Asahikawa, Japan.
  • Takamaru H; Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Yamada K; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Nozawa H; Department of Surgery, Coloproctology Center Takano Hospital, Kumamoto, Japan.
  • Takayama T; Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
  • Togashi K; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Shinto E; Department of Coloproctology, Aizu Medical Center Fukushima Medical University, Fukushima, Japan.
  • Torisu T; Department of Surgery, National Defense Medical College, Tokorozawa, Japan.
  • Toyoshima A; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Ohmiya N; Department of Colorectal Surgery, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Kato T; Department of Advanced Endoscopy, Fujita Health University School of Medicine, Aichi, Japan.
JCO Glob Oncol ; 10: e2300392, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38330276
ABSTRACT

PURPOSE:

Limited information is available regarding the characteristics and outcomes of stage IV small bowel adenocarcinoma (SBA) in Japan. This study examined the clinical and pathological characteristics and outcomes according to the treatment strategies in patients with stage IV SBA.

METHODS:

This retrospective observational study used the data of patients with jejunal or ileal adenocarcinoma collected by the Small Bowel Malignant Tumor Project of the Japanese Society for Cancer of the Colon and Rectum. Descriptive statistics were expressed as the mean (standard deviation) or median (range). Survival analysis was performed using Kaplan-Meier curves and pairwise log-rank tests.

RESULTS:

Data from 128 patients were analyzed. The treatment strategies were chemotherapy alone (26 of 128, 20.3%), surgery alone (including palliative surgery; 21 of 128, 16.4%), surgery + chemotherapy (74 of 128, 57.8%), and best supportive care (7 of 128, 5.5%). The median (range) overall survival was 16 (0-125) months overall, and 11 (1-38) months, 8 (0-80) months, 18 (0-125) months, and 0 (0-1) months for the chemotherapy, surgery, surgery + chemotherapy, and best supportive care groups, respectively. Three main categories of chemotherapeutic regimen were used a combination of fluoropyrimidine and oxaliplatin (F + Ox), fluoropyrimidine and irinotecan (F + Iri), and single-agent fluoropyrimidine. Among patients treated with chemotherapy, the median (range) OS was 16 (1-106) months overall, and 17 (1-87) months, 29 (7-39) months, and 16 (1-106) months in patients treated with fluoropyrimidine, F + Iri, and F + Ox, respectively.

CONCLUSION:

Patients treated with surgery, chemotherapy, or both had a better prognosis than those who received best supportive care. Among patients who received chemotherapy, survival did not differ according to the chemotherapeutic regimen.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: JCO Glob Oncol Año: 2024 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: JCO Glob Oncol Año: 2024 Tipo del documento: Article País de afiliación: Japón